Heart disease and single-vitamin supplementation

American Journal of Clinical Nutrition

Volumn 85, Issue 1, 2007, Pages

  Traber, Maret G ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Biomarkers; Carboxyethyl hydroxy chromans; Folic acid; Oxidative stress; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BIOLOGICAL MARKER; CHOLESTEROL; PLACEBO; VITAMIN B GROUP;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DIET THERAPY; DIETARY INTAKE; DISEASE MARKER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; HEART DISEASE; HUMAN; LIPID PEROXIDATION; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 33846182968     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/85.1.293s     Document Type: Conference Paper

References (92)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151.
2. Shekelle PG, Morton SC, Jungvig LK, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med 2004;19:380-9.
3. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA 2002;288:2569-78.
4. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:655-66.
5. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21.
6. Brass EP, Allen SE, Melin JM. Potential impact on cardiovascular public health of over-the-counter statin availability. Am J Cardiol 2006;97:851-6.
7. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
8. Burton GW, Joyce A, Ingold KU. First proof that vitamin E is major lipid-soluble, chain-breaking antioxidant in human blood plasma. Lancet 1982;8293:327.
9. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 1991;32:1325-32.
10. Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 1993;300:535-43.
11. Diaz MN, Frei B, Vita JA, Keaney JFJ. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16.
12. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
13. Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46:389-403.
14. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-101.
15. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 2005;25:151-74.
16. Devaraj S, Jialal I. α-Tocopherol decreases interleukin-1β release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 1999;19:1125-33.
17. Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 1994;94:592-600.
18. Cominacini L, Garbin U, Pasini AF, et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 1997;22:117-27.
19. Martin A, Foxall T, Blumberg JB, Meydani M. Vitamin E inhibits lowdensity lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro. Arterioscler Thromb Vasc Biol 1997;17:429-36.
20. Islam KN, Devaraj S, Jialal I. α-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells. Circulation 1998;98:2255-61.
21. Azzi A, Boscoboinik D, Marilley D, Ozer NK, Stauble B, Tasinato A. Vitamin E: a sensor and an information transducer of the cell oxidation state. Am J Clin Nutr 1995;62(suppl):1337S-46S.
22. Freedman JE, Farhat JH, Loscalzo J, Keaney JFJ. α-Tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996;94:2434-40.
23. Steiner M. Influence of vitamin E on platelet function in humans. J Am Coll Nutr 1991;10:466-73.
24. Cachia O, Benna JE, Pedruzzi E, Descomps B, Gougerot-Pocidalo MA, Leger CL. α-Tocopherol inhibits the respiratory burst in human monocytes. Attenuation of p47(phox) membrane translocation and phosphorylation. J Biol Chem 1998;273:32801-5.
25. Keaney JF Jr, Simon DI, Freedman JE. Vitamin E and vascular homeostasis: implications for atherosclerosis. FASEB J 1999;13:965-75.
26. Desrumaux C, Deckert V, Athias A, et al. Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells. FASEB J 1999;13:883-92.
27. Wu D, Liu L, Meydani M, Meydani SN. Vitamin E increases production of vasodilator prostanoids in human aortic endothelial cells through opposing effects on cyclooxygenase-2 and phospholipase A2. J Nutr 2005;135:1847-53.
28. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
29. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.
30. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55.
31. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease(SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-8.
32. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89-95.
33. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002;25:1919-27.
34. Hodis HN, Mack WJ, LaBree L, et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002;106:1453-9.
35. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338-47.
36. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:56-65.
37. Jialal I, Devaraj S. Scientific evidence to support a vitamin E and heart disease health claim: research needs. J Nutr 2005;135:348-53.
38. Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academy Press, 2000.
39. Traber MG, Sokol RJ, Burton GW, et al. Impaired ability of patients with familial isolated vitamin E deficiency to incorporate alpha-tocopherol into lipoproteins secreted by the liver. J Clin Invest 1990;85:397-407.
40. Traber MG, Sokol RJ, Kohlschütter A, et al. Impaired discrimination between stereoisomers of α-tocopherol in patients with familial isolated vitamin E deficiency. J Lipid Res 1993;34:201-10.
41. Terasawa Y, Ladha Z, Leonard SW, et al. Increased atherosclerosis in hyperlipidemic mice deficient in alpha-tocopherol transfer protein and vitamin E. Proc Natl Acad Sci U S A 2000;97:13830-4.
42. Leonard SW, Terasawa Y, Farese RV Jr, Traber MG. Incorporation of deuterated RRR- or all-rac-α-tocopherol into plasma and tissues of α-tocopherol transfer protein-null mice. Am J Clin Nutr 2002;75:555-60.
43. Mustacich DJ, Shields J, Horton RA, Brown MK, Reed DJ. Biliary secretion of alpha-tocopherol and the role of the mdr2 P-glycoprotein in rats and mice. Arch Biochem Biophys 1998;350:183-92.
44. Burton GW, Traber MG, Acuff RV, et al. Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am J Clin Nutr 1998;67:669-84.
45. Brigelius-Flohé R, Traber MG. Vitamin E: function and metabolism. FASEB J 1999;13:1145-55.
46. Kiyose C, Saito H, Kaneko K, et al. Alpha-tocopherol affects the urinary and biliary excretion of 2,7,8-trimethyl-2-(2′-carboxyethyl)-6- hydroxychroman, gamma-tocopherol metabolite, in rats. Lipids 2001;36:467-72.
47. Swanson JE, Ben RN, Burton GW, Parker RS. Urinary excretion of 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman is a major route of elimination of gamma-tocopherol in humans. J Lipid Res 1999;40:665-71.
48. Stahl W, Graf P, Brigelius-Flohe R, Wechter W, Sies H. Quantification of the alpha- and gamma-tocopherol metabolites 2,5,7,8-tetramethyl-2-(2′- carboxyethyl)-6-hydroxychroman and 2,7,8-trimethyl-2-(2′-carboxyethyl)-6- hydroxychroman in human serum. Anal Biochem 1999;275:254-9.
49. Pope SA, Burtin GE, Clayton PT, Madge DJ, Muller DP. Synthesis and analysis of conjugates of the major vitamin E metabolite, alpha-CEHC. Free Radic Biol Med 2002;33:807-17.
50. Leonard SW, Paterson E, Atkinson JK, Ramakrishnan R, Cross CE, Traber MG. Studies in humans using deuterium-labeled α- and γ-tocopherol demonstrate faster plasma γ-tocopherol disappearance and greater γ-metabolite production. Free Radic Biol Med 2005;38:857-66.
51. Traber MG, Siddens LK, Leonard SW, et al. α-Tocopherol modulates Cyp3a expression, increases γ-CEHC production and limits tissue γ-tocopherol accumulation in mice fed high γ-tocopherol diets. Free Radic Biol Med 2005;38:773-85.
52. Kluth D, Landes N, Pfluger P, et al. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma-tocotrienol in mice. Free Radic Biol Med 2005;38:507-14.
53. Ikeda S, Tohyama T, Yamashita K. Dietary sesame seed and its lignans inhibit 2,7,8-trimethyl-2(2′-carboxyethyl)-6-hydroxychroman excretion into urine of rats fed gamma-tocopherol. J Nutr 2002;132:961-6.
54. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23.
55. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002;62:638-46.
56. Rushmore TH, Kong AN. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 2002;3:481-90.
57. Landes N, Pfluger P, Kluth D, et al. Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol 2003;65:269-73.
58. Zhou C, Tabb MM, Sadatrafiei A, Grun F, Blumberg B. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 2004;32:1075-82.
59. Dussault I, Yoo HD, Lin M, et al. Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc Natl Acad Sci U S A 2003;100:833-8.
60. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001;21:1320-6.
61. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
62. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.
63. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70.
64. Lee AJ, Kosh JW, Conney AH, Zhu BT. Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. J Pharmacol Exp Ther 2001;298:420-32.
65. Bruno RS, Ramakrishnan R, Montine TJ, Bray TM, Traber MG. α-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. Am J Clin Nutr 2005;81:95-103.
66. Bruno RS, Leonard SW, Atkinson JK, et al. Faster vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med 2006;40:689-97.
67. Hensley K, Benaksas EJ, Bolli R, et al. New perspectives on vitamin E: gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 2004;36:1-15.
68. Leonard SW, Bruno RS, Paterson E, et al. 5-Nitro-γ-tocopherol increases in human plasma exposed to cigarette smoke in-vitro and invivo. Free Radic Biol Med 2003;38:813-9.
69. Morton LW, Ward NC, Croft KD, Puddey IB. Evidence for the nitration of gamma-tocopherol in vivo: 5-nitro-gamma-tocopherol is elevated in the plasma of subjects with coronary heart disease. Biochem J 2002;364:625-8.
70. Williamson KS, Gabbita SP, Mou S, et al. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide 2002;6:221-7.
71. Sowell J, Frei B, Stevens JF. Vitamin C conjugates of genotoxic lipid peroxidation products: structural characterization and detection in human plasma. Proc Natl Acad Sci U S A 2004;101:17964-9.
72. Sowell J, Conway HM, Bruno RS, Traber MG, Frei B, Stevens JF. Ascorbylated 4-hydroxy-2-nonenal as a potential biomarker of oxidative stress response. J Chromatogr B Analyt Technol Biomed Life Sci 2005;827:139-45.
73. Roberts II LJ, Fessel JP. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 2004;128:173-86.
74. Davies SS, Zackert W, Luo Y, Cunningham CC, Frisard M, Roberts LJ 2nd. Quantification of dinor, dihydro metabolites of F(2)-isoprostanes in urine by liquid chromatography/tandem mass spectrometry. Anal Biochem 2006;348:185-91.
75. Gao L, Yin H, Milne GL, Porter NA, Morrow JD. Formation of F-ring isoprostane-like compounds(F3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem 2006;281:14092-9.
76. Mastaloudis A, Leonard SW, Traber MG. Oxidative stress in athletes during extreme endurance exercise. Free Radic Biol Med 2001;911-22.
77. Mastaloudis A, Morrow JD, Hopkins DW, Deveraj S, Traber MG. Antioxidant supplementation prevents exercise-induced lipid peroxidation, but not inflammation, in ultramarathon runners. Free Radic Biol Med 2004;36:1329-41.
78. Maras JE, Bermudez OI, Qiao N, Bakun PJ, Boody-Alter EL, Tucker KL. Intake of alpha-tocopherol is limited among US adults. J Am Diet Assoc 2004;104:567-75.
79. Moshfegh A, Goldman J, Cleveland L. What we eat in America, NHANES 2001-2001: usual nutrient intakes from food compared to dietary reference intakes. Washington, DC: US Department of Agriculture, Agricultural Research Service, 2005.
80. Bruno RS, Leonard SW, Park S-I, Zhao Y, Traber MG. Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled α-tocopheryl acetate. Am J Clin Nutr 2006;83:299-304.
81. Knekt P, Ritz J, Pereira MA, et al. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr 2004;80:1508-20.
82. Muntwyler J, Hennekens CH, Manson J, Buring JE, Gaziano JM. Vitamin supplement use in a low-risk population of US male physicians and subsequent cardiovascular mortality. Arch Intern Med 2002;162:1472-6.
83. Holmquist C, Larsson S, Wolk A, de Faire U. Multivitamin supplements are inversely associated with risk of myocardial infarction in men and women-Stockholm Heart Epidemiology Program (SHEEP). J Nutr 2003;133:2650-4.
84. Harper CR, Jacobson TA. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. Am J Cardiol 2005;96:1521-9.
85. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282-7.
86. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
87. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
88. Salonen RM, Nyyssonen K, Kaikkonen J, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003;107:947-53.
89. Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002;359:1108-13.
90. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004;61:82-8.
91. Ascherio A, Weisskopf MG, O'Reilly EJ, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol 2005;57:104-10.
92. Ford ES, Ajani UA, Mokdad AH. Brief communication: the prevalence of high intake of vitamin E from the use of supplements among U.S. adults. Ann Intern Med 2005;143:116-20.